Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · GUJARAT THEMIS BIOSYN LTD · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
GUJARAT THEMIS BIOSYN LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, – (all audited; no estimate years)
₹ crore · consolidated
Revenue
EBITDA (ex other income)
margin %
Owners' profit
EPS, as reported (₹)
ROE % · ROCE %
Debt / equity (x)
Cash from operations
Capex
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GUJARAT THEMIS BIOSYN LTD · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 1 quarters
₹ crore
Q1 FY27
Revenue
44
Profit before tax
15
Net profit
11
EPS (₹)
1.02
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
Company
M.cap ₹ cr
P/E
P/B
EV/EBITDA
ROE %
ROCE %
Rev CAGR 5y %
EBITDA m. %
SUN PHARMACEUTICAL IND L
4,21,677
34.9
5.03
22.6
13.7
17.5
11.8
32.3
DIVI S LABORATORIES LTD
2,53,976
87.0
15.15
65.5
15.3
18.8
8.7
42.8
TORRENT PHARMACEUTICALS L
1,54,957
73.1
8.81
38.5
12.2
8.0
11.8
33.1
LAURUS LABS LIMITED
1,17,877
107.7
21.70
65.6
16.4
17.2
7.2
32.0
ZYDUS LIFESCIENCES LTD
1,17,315
26.2
3.97
15.1
17.3
18.0
12.4
25.2
DR. REDDY S LABORATORIES
1,11,506
34.5
2.92
14.9
10.9
13.0
12.1
15.0
CIPLA LTD
1,10,320
32.7
3.20
16.9
11.2
14.7
8.0
19.7
MANKIND PHARMA LIMITED
1,02,829
50.3
6.21
28.3
11.7
10.8
—
27.3
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
Metric
Company
Group median
Rank
Better than
P/E (TTM)
349.5
30.8
155 of 158
2%
EBITDA margin
47.8
17.5
4 of 165
98%
Market cap
3884
806
64 of 181
65%
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · GUJARAT THEMIS BIOSYN LTD · 29 October 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
Date · filing
Category
Importance
Next day %
5-day %
27 Oct 2026 · Investor and analyst meet set for 5 November to discuss FY27 results
board shareholder meetings
low
—
—
27 Oct 2026 · Board to approve September 2026 quarterly and half-year results
results
low
—
—
23 Oct 2026 · Clarification of erroneous credit rating filing
compliance
minimal
—
—
12 Oct 2026 · RTA Compliance Certificate under SEBI Reg 74(5) for Sep 2026 quarter
compliance
minimal
—
—
9 Oct 2026 · Credit rating downgraded on sharp profitability decline
credit debt
medium
—
—
1 Oct 2026 · 45th AGM results: 8 of 9 resolutions passed; promoter loan proposal rejected
board shareholder meetings
low
—
—
1 Oct 2026 · 56th AGM: All 5 resolutions approved with over 99.99% majority
30 Sept 2026 · Revised proceedings of 45th AGM filed to correct typographical error
board shareholder meetings
low
—
—
30 Sept 2026 · Dividend of Re 0.67/share, preferential equity issue, and AOA amendment approved
corporate actions
medium
—
—
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
Where a broker report shows
This document shows
Why
A rating (BUY / ADD / REDUCE / SELL)
A state: the latest filed quarter and the measured reactions
an event is a fact; a rating is an opinion that requires SEBI RA registration
A target price and upside
The current price and the multiples against the group
a target is a forecast; a multiple is a measurement
Estimate years marked E
More audited years; no estimates
MarketPing publishes no forecasts — your own model lives on the Models page
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
